Key Highlights
- Novo Nordisk shares declined more than 9% following disappointing ZEUS cardiovascular trial outcomes.
- The study demonstrated reduced inflammation markers but failed to decrease major heart-related events.
- The experimental drug ziltivekimab posted a 0.99 hazard ratio compared to placebo in phase 3 testing.
- Higher serious infection rates were observed in the treatment group, though total mortality remained comparable.
- Two ongoing trials, HERMES and ARTEMIS, are projected to deliver results in the first half of 2027.
Shares of Novo Nordisk declined 9.18% to $46.85 following the announcement that its ZEUS cardiovascular trial did not achieve its primary endpoint of reducing major adverse cardiac events. The disappointing outcome raised questions about ziltivekimabs clinical potential, even though the drug demonstrated clear biological effects on inflammation markers associated with heart and kidney conditions. The company emphasized that this development will not impact its adjusted operating profit forecast for the full 2026 fiscal year.
Novo Nordisk A/S, NVO
ZEUS Study Falls Short of Primary Cardiovascular Endpoint
Novo Nordisk enrolled more than 6,300 participants with established cardiovascular disease, chronic kidney disease, and elevated systemic inflammation in its phase 3 ZEUS investigation. The randomized, double-blind trial evaluated a monthly 15-milligram dose of ziltivekimab against a placebo control over an extended observation period. The primary composite endpoint included cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.
Treatment with ziltivekimab successfully lowered levels of free interleukin-6 and high-sensitivity C-reactive protein, demonstrating robust pharmacological activity against the intended biological targets. Despite these measurable anti-inflammatory effects, the therapy did not produce a statistically significant reduction in major adverse cardiovascular events when compared with placebo. The trial yielded a hazard ratio of 0.99, with the 95% confidence interval spanning 0.88 to 1.11.
The safety profile showed general adverse events and serious adverse events occurring at similar rates in both study arms. However, participants receiving ziltivekimab experienced a higher incidence of serious infections, an outcome consistent with the known immunological effects of blocking the IL-6 signaling pathway. Notably, all-cause mortality rates showed no significant difference between the treatment and placebo cohorts throughout the study duration.
Company Maintains Commitment to Ongoing Cardiovascular Studies
Novo Nordisk announced it will advance two additional cardiovascular outcome trials evaluating ziltivekimab, despite the setback in ZEUS. The HERMES trial is examining the drugs efficacy in patients with established heart failure who remain at elevated cardiovascular risk. Separately, the ARTEMIS study is assessing ziltivekimab in individuals who have recently experienced an acute myocardial infarction and face ongoing cardiovascular complications.
The company anticipates top-line data from both trials to become available in early 2027, according to its updated clinical development schedule. These investigations focus on distinct patient populations and disease contexts, which could potentially yield different efficacy profiles compared to the ZEUS cohort. Consequently, Novo Nordisk will retain critical data points before making final strategic decisions regarding ziltivekimabs commercial pathway.
The failed ZEUS trial will result in a non-cash impairment expense recorded in the third quarter of fiscal year 2026. Nevertheless, the company confirmed that this accounting adjustment will not require revision to its previously communicated adjusted operating profit outlook for the full year. The sharp stock price decline underscores investor concerns about the reduced commercial potential of the cardiovascular pipeline following the trials failure to meet its primary objective.
The post Novo Nordisk (NVO) Stock Tumbles 9% as ZEUS Trial Falls Short of Cardiovascular Goals appeared first on Blockonomi.